Crossmark

Stromal PDGFR-beta expression is a prognostic factor in high-grade serous ovarian cancer patients but is it also predictive for response to antiangiogenic treatment?

Crossref DOI link: https://doi.org/10.1007/s00432-025-06090-4

Published Online: 2025-01-24

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Volk, Annabelle

von Bülow, Charlotte

Stern, Aysche

Simon, Ronald

Burandt, Eike

Sauter, Guido

Schmalfeldt, Barbara

Oliveira-Ferrer, Leticia
Funding

Funding for this research was provided by:

Wilhelm Sander-Stiftung (2017.088.1, 2017.088.1, 2017.088.1, 2017.088.1, 2017.088.1, 2017.088.1, 2017.088.1, 2017.088.1)

Universitätsklinikum Hamburg-Eppendorf (UKE)
License Information

Text and Data Mining valid from 2025-01-24

Version of Record valid from 2025-01-24
More Information

Article History

Received: 2 December 2024

Accepted: 9 January 2025

First Online: 24 January 2025

Declarations

:

: The authors declare no competing interests.

Document is current

Any future updates will be listed below